Clinical Blog
Published: January 31, 2023

Pharma’s Biggest Takeaways From the 2023 J.P. Morgan Healthcare Conference

At J.P. Morgan’s 41st annual healthcare conference, there was no shortage of innovative discussions. We’ve rounded up some of the biggest themes from this year’s conference:

Connected drug delivery devices are gaining traction among top pharma companies

As medication non-adherence continues to plague the global life sciences industry – more than $600 billion in annual revenue is lost1 – many pharmaceutical companies are evaluating new approaches to improving patient engagement, including embedded sensors that capture data through drug delivery devices. One of the biggest selling points for organizations is that connected drug delivery devices can play a huge role in boosting adherence and compliance. Devices that can detect and capture data around patient-administered therapy, such as dose timing, volume, and technique, have become an increasingly popular choice among leading organizations. Patients are more likely to refill and take their medications on time, and correctly, if they can be prompted to do so and have a record of dosing history. 

An industry-wide pivot toward in-home care is escalating

The pandemic quickly reshaped how we deliver care. Global social isolation measures rendered in-home services through telehealth and virtual care platforms a critical alternative to in-clinic primary care. As the world slowly returns to a pre-pandemic normal, in-home care continues to supplement in-person visits, especially given telehealth’s emphasis on patient convenience. Pharmaceutical companies looking to provide a convenient, frictionless experience for patients will need to ensure their products are easy to learn and use under limited clinical supervision, and can remotely capture data signals.

Product differentiation is crucial for leveraging value to all stakeholders, especially patients

In a saturated market filled with generic alternatives for common disease types, product differentiation is more critical than ever. Pharmaceutical companies will not only need to reconsider how their products provide differentiated value to payers and providers, but also consider how to meet and surpass patient expectations. Efficacy alone is not enough – patients are demanding new and improved product benefits, including behavior change coaching and support. 

Decentralized clinical trials successfully improve diversity of trial participants and reduce barriers to patient identification and recruitment

When clinical trial patients accurately represent the group of people most affected by a particular disease, the study’s scientific and financial robustness increase, and real-world outcomes improve. Decentralized clinical trials (DCTs) show promise in improving patient diversity in clinical trials.2 Beyond that benefit, DCTs – and, specifically, the digital tools that enable virtual trial execution – improve data reliability while increasing convenience for patients and site staff. Pharmaceutical and life sciences companies will need to leverage the right digital solutions to meet patient expectations and provider demands, comply with new regulations,3 and to continue reaping the benefits of DCTs, including lower costs, more efficient patient identification and recruitment, increased patient participation, and higher retention rates. 

Interested in learning more about how Propeller can help your organization integrate connected drug delivery? Email

1 Fierce Pharma, 2016. Nonadherence costs pharma $600B-plus in annual sales: study.
2 Chaudhry, et al. 2022. Myths about diversity in clinical trials reduce return on investment for industry. Nature Medicine
3 Bloomberg Law, 2023. Diversity in Clinical Trials at FDA Gets a Boost From New Law

You Might Also Like

Reducing Clinician Burnout: The Power of Using Digital Tools Effectively

It's no secret that health systems are feeling strained, with 47% of physicians experiencing symptoms of clinician burnout.1 An overwhelming amount of clinical data, jam-packed days with little time to connect with patients, and a lengthy list of responsibilities are leaving healthcare professionals feeling drained.

Clinician exhaustion can lead to reduced job satisfaction, increased turnover, and a decrease in the quality of care provided to patients. But burnout isn’t only harmful to teams — it can also cause financial strain on health systems. According to a study by the Annals of Internal Medicine, clinician exhaustion accumulates approximately $4.6 billion in costs due to turnover and reduced clinic hours.2

But when health systems use digital tools the right way, they can reduce the risk of clinician burnout and increase patient care coordination.

From 2010 to Today: Happy Birthday, Propeller!

Today marks an incredible milestone: Propeller Health's 13th birthday. What began as a quest to solve a public health problem has turned into a global precision digital health company driving meaningful, measurable change in the industry. 

Recognizing early on that creating value for all parties in health – health systems, clinicians, payers, and pharmaceutical companies – is essential in order to drive sustainable change, we’ve spent the past 13 years pioneering innovative solutions that always keep the patient at the center. Our story is one of hard work, dedication, collaboration, and above all, a mission to uplift every person living with a chronic disease so they can breathe easier, stay healthier, and live better lives. 

Propeller was founded on the heels of a then-mysterious string of asthma attacks in Barcelona in the 1980s. It took 8 years for experts to identify soybean dust – not yet recognized as an allergen – as the trigger. One CDC disease detective envisioned a better way to monitor public health: by using technology to track medication usage and symptoms. With this mission, Propeller was born. 

Coming to AAAAI 2023: Propeller’s latest asthma research

The American Academy of Allergy, Asthma and Immunology (AAAAI) has accepted five abstracts examining the latest data from Propeller Health and ResMed.

Our findings on asthma care, which include analyzing the direct and indirect cost-savings associated with a digital intervention in uncontrolled asthma, will be presented at the AAAAI Annual Meeting on February 24-27. Read brief summaries of each abstract below or click the links to view them online.

Direct and indirect cost-savings associated with a digital intervention in uncontrolled asthma: A literature-based estimate